Drug Repurposing Market Size, Share and Trends Analysis
The Drug Repurposing Market was valued at USD 12.5 billion in 2023 and is projected to reach USD 27.8 billion by 2032, growing at a CAGR of 9.3%. Key drivers include AI advancements and rising R&D costs.
Revenue, 2023
$12.5B
Forecast, 2032
$27.8B
CAGR, 2024-2032
9.3%
Report Coverage
North America
Market Overview
The Drug Repurposing Market is experiencing robust growth, driven by AI advancements and rising R&D costs, with a projected CAGR of 9.3% from 2024 to 2032, reaching USD 27.8 billion by 2032.
Market Stage
High growth
Adoption Level
Growing
Key Trends
Market Forecast & Data
Base Year (2023)
$13.7B
Forecast (2032)
$27.8B
CAGR (2024-2032)
9.3%
North America
#1Largest market: USA
Europe
#2Largest market: Germany
Market Dynamics
- Rising drug development costs
- Advancements in AI and genomics
- Increasing prevalence of chronic diseases
- Need for faster therapeutic solutions
Market Segmentation
Regional Analysis
North America
Lead: USADominates the market due to advanced healthcare infrastructure and substantial investment in AI-driven drug discovery platforms.
Europe
Lead: GermanyStrong regulatory framework supports collaborative research initiatives across multiple countries.
Asia Pacific
Lead: ChinaRapidly growing due to increasing healthcare spending and government initiatives promoting biotech innovation.
Country-Level Analysis
| Country | Share | Growth |
|---|---|---|
| USA | 25.0% | +8.5% |
| Germany | 10.0% | +7.5% |
| China | 15.0% | +11.5% |
Competitive Landscape
Pfizer
USA
Leading the market with AI-driven repurposing initiatives in oncology and rare diseases, supported by strategic acquisitions and partnerships.
Roche
Switzerland
Investing heavily in AI and genomics for repurposing, particularly in oncology and immunology, with a robust pipeline of repurposed drugs.
AstraZeneca
UK
Focusing on repurposing for oncology and respiratory diseases through computational biology and AI platforms.
IBM
USA
Leveraging Watson Health for AI-based drug repurposing, offering analytical tools to pharmaceutical companies.
Novartis
Switzerland
Active in repurposing for rare diseases and oncology, with a focus on biologics through R&D initiatives.
BenevolentAI
UK
Specializing in AI-driven drug repurposing, with a focus on neurological disorders and cancer.
Recent Developments
Announced the launch of a new AI-powered platform for repurposing drugs for rare diseases, with the first candidate expected to enter clinical trials in 2026.
Partnered with a startup specializing in genomics-based drug repurposing to accelerate oncology drug discovery.
Secured a major contract with a European pharmaceutical company to deploy its Watson Health platform for repurposing in cancer treatment.
Acquired a biotech firm focused on repurposing biologics for autoimmune diseases, expanding its pipeline in this area.